Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $18.00.

Several brokerages have issued reports on ELAN. Piper Sandler reaffirmed a “neutral” rating and set a $19.00 price target (up previously from $18.00) on shares of Elanco Animal Health in a report on Monday, May 13th. Barclays decreased their target price on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Friday.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN opened at $14.43 on Monday. The company has a market capitalization of $7.13 billion, a price-to-earnings ratio of -5.45, a P/E/G ratio of 1.74 and a beta of 1.45. The firm’s 50 day simple moving average is $16.43 and its 200 day simple moving average is $15.68. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.29 and a quick ratio of 1.96. Elanco Animal Health has a fifty-two week low of $8.52 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.08. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The business’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period last year, the business earned $0.45 EPS. As a group, sell-side analysts forecast that Elanco Animal Health will post 0.93 earnings per share for the current year.

Insider Buying and Selling

In related news, Director William F. Doyle purchased 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The stock was acquired at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the acquisition, the director now owns 76,330 shares of the company’s stock, valued at approximately $1,296,083.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.57% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sapient Capital LLC purchased a new position in shares of Elanco Animal Health during the 4th quarter valued at $2,046,000. Phocas Financial Corp. bought a new position in Elanco Animal Health in the 4th quarter worth about $3,857,000. Bank of Nova Scotia bought a new position in Elanco Animal Health in the 4th quarter worth about $4,004,000. Vanguard Group Inc. boosted its position in shares of Elanco Animal Health by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after acquiring an additional 467,196 shares during the last quarter. Finally, Ancora Advisors LLC bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $37,189,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.